Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy

Angelo Massimiliano D’Erme1,2
Marco Romanelli2
Andrea Chiricozzi2
1Dermatology Unit, Livorno Hospital, Livorno, 2Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Abstract: Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD.

Keywords: dupilumab, atopic dermatitis, eczema, IL-4, IL-13, biologics

Introduction

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases affecting up to 25% of children in industrialized countries.1 One-third of cases persist into adulthood, comprising a prevalence of 2%–10%.2–4 AD is not just a skin disease as it may represent the first manifestation of the so-called atopic march, a spectrum of interconnected disorders, including rhinitis, conjunctivitis, and asthma, that may follow skin symptoms later in life.5–6

Because the prevalence of AD is lower in rural and nonindustrialized countries,4 the hygiene hypothesis, in which the lack of exposure to antigens in early life would induce immune imbalance, favoring a proinflammatory Th2 response that drives the immune dysregulation in AD, has been proposed.5,7,8

Immunopathogenesis of AD

AD pathogenesis represents a complex mechanism, including a defective epidermal barrier, caused by an altered expression of keratinocyte differentiation genes (eg, cornified cell envelope-related genes) and an abnormal content of extracellular lipids, resulting in increased transepidermal water loss and permeation to allergens, irritants, and microbes.9–11

Beside this intrinsic impairment of the keratinocyte differentiation process, AD lesional skin shows a marked infiltration of T cells, both CD4+ and CD8+
T cells, dendritic cells (DCs), Langerhans cells, and other immune cells, including eosinophils, mast cells, and IgE-producing plasma cells. Classically, AD is considered as a Th2-dominant disease, as an enhanced signal of the Th2 pathway is detected in AD lesional skin and, to a lesser strength, in non-lesional skin. The increased expression of Th2-derived cytokines, namely, IL-4, IL-5, IL-13, and IL-31, is correlated with high levels of Th2 chemoattractants and activating factors such as CCL-17, CCL-18, CCL-22, CCL-26, CCL-27, and TSLP.

**IL-4 and IL-13**

The centrality of the Th2 cytokines is due to their capability of 1) inducing IgE class switching; 2) promoting Th2 survival; 3) recruitment of eosinophils; 4) mediating pruritus; and 5) inhibiting keratinocyte terminal differentiation and AMP production (Figure 1). Particularly, IL-4 and IL-13 are considered as the Th2-signature cytokines and master mediators in AD pathogenesis as they act on various cells involved in AD (ie, keratinocytes, T cells, DCs, and eosinophils), signaling through the same receptor, the IL-4Rα receptor. Although the immune response is polarized toward a Th2 response, other T-cell subsets participate in AD pathogenesis, including T22 cells and both CD4+ and CD8+ T cells producing IL-22-, IL-17-, and IFN-γ-secreting cells. Based on the dominant pathways driving AD inflammation, intrinsic AD may be distinguished from the extrinsic form. Indeed, the extrinsic form (~80% of AD cases) shows high IgE serum levels associated with a Th2-skewed immune polarization and a less pronounced T22 signal, whereas the intrinsic form (the remaining 20%) is characterized by low IgE titers and a Th2 response, with a marked upregulation of the Th17 and Th22 axes. In this scenario, key mediators, such as IL-4, IL-13, and IL-22, have been identified as therapeutic targets for the development of new agents that selectively inhibit their signaling. One of the promising agents that is currently being developed for the treatment of AD is dupilumab, an IL-4Rα antagonist.

**Clinical phenotypes and endophenotypes of AD toward personalized treatment**

AD is characterized by a wide range of heterogeneity either in the onset (ie, infant–adolescent–adult), course, and presentation (different manifestation of eczema among either the age, the clinical features, or the area involved) or in the comorbidities (eg, the presence of atopy and normal IgE distinguishes an intrinsic AD from an extrinsic or IgE-associated AD). All these variants are due to the complex interactions between individual genetic and environmental factors involved in AD that lead to epidermal barrier dysfunction, innate and adaptive abnormalities of the immune system (an initial Th2 phase followed by a chronic Th1 phase), and cutaneous microbiome dysbiosis. Despite all these AD variants, the diagnosis is clinical and no diagnostic biomarkers dissecting AD from other inflammatory disorders have been identified yet. Since AD involves more than one subtype, the discovery, validation, and use of objective markers will achieve a more personalized clinical and treatment approach.

Nowadays, treatment choice is based on disease severity and symptoms, namely, pruritus and the “trouble sleeping”. The commonly used assessment tools, both in trial setting and in daily practice, include the Eczema Area and Severity Index (EASI), a composite score assessing objective signs, and the SCORing Atopic Dermatitis (SCORAD), evaluating both signs and symptoms. Management and treatment in the short (flares) and long periods may become challenging because of the individual symptomatic variability and the limited array of therapeutics currently available.

**Current treatment for AD**

AD treatment includes “basic therapy” focused on emollients and moisturizing compounds, on the avoidance of specific or unspecific triggering factors, and on educational programs/psychological counseling.

First-line pharmacological treatment is based on the use of topical medications: topical corticosteroids and topical calcineurin inhibitors, namely, tacrolimus and pimecrolimus. Topical agents represent the mainstay of therapy in patients with mild-to-moderate disease and are used either for the management of exacerbation or, more recently, for proactive therapy. The long-term intermittent (twice weekly)
anti-inflammatory therapy aims to prevent relapses and to keep the skin free of eczema. This strategy has been proven successful in improving the clinical management and is, notably, associated with pharmacoeconomic benefits.29–31

Phototherapy (ultraviolet A1 [UVA1] wavelength or ultraviolet B [UVB] 311 nm) can be adjuncted in controlling challenging cases not responsive to topical treatments, such as second-line treatment, with good results.29–31

Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The treatment choice depends on AD severity, patient’s features, physician’s experience, and drug availability.5 Although the majority of evidence exists in adult populations, four systemic immunosuppressive drugs have also demonstrated to be efficacious in adults and children: cyclosporine, mycophenolate mofetil, methotrexate, and azathioprine.32,33 Among them, cyclosporine is the only drug approved for the treatment of AD. According to the European Guidelines, other systemic medications are suggested in case of no response to cyclosporine and/or when contraindications to cyclosporine occur.29–31,33 No biologic drugs targeting AD-signature mediators have been approved yet. Nevertheless, off-label use, sometimes successful, of biologics approved for other indications, such as omalizumab, ustekinumab, and rituximab, has been reported.35

Thus, the current therapeutic paradigm in AD is limited and its management becomes challenging in most cases. Furthermore, some side effects of these medications, such as nephrotoxicity and risk of hypertension during cyclosporine treatment, limit their use.

**Dupilumab: developing the new era in the treatment of AD**

Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets, similar to what occurred in the past decade in psoriasis.28,36 Th2 cells and their key cytokines, such as IL-4, IL-13, IL-5, TSLP, and IgE, constitute emerging targets for new compounds that have been or are currently being tested in clinical trials.28,37 In the last few years, some biologics, such as omalizumab (anti-IgE) and mepolizumab (anti-IL-5), have been previously tested in patients with AD, although no significant benefits were described.33,38–40 On the contrary, the blockade of IL-4/IL-13-mediated signaling through the receptor antagonism was proven to be a successful therapeutic strategy in AD. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit, which is a component of Type I and Type II IL-4 receptors and the IL-13 receptor system. Because of this binding, dupilumab is able to effectively inhibit the IL-4 and IL-13 signaling, with pivotal effect in Th2 inflammatory atopic response (Figure 1).41 IL-4 and IL-13 increase the expression of important chemokines such as TARC and eotaxin-3 and attract Th2 cells and eosinophils. They are also important in AD because they contribute directly to barrier dysfunction (acting on keratinocyte differentiation and barrier protein, lipids, and production of antimicrobial peptides).42

**Mechanistic study**

To define dupilumab’s spectrum of action on AD skin, a comprehensive gene expression analysis was performed, comparing pretreatment with posttreatment lesional skin and non-lesional skin. Biopsy specimens were obtained from 18 adult patients with moderate-to-severe chronic AD participating in two Phase 1 multicenter, randomized, double-blind, placebo-controlled trials testing weekly subcutaneous injections of dupilumab 150 or 300 mg or placebo for 4 weeks.42 Disease severity, assessed by EASI, was significantly improved in adults treated with dupilumab compared to the placebo group as EASI-50, representing at least 50% reduction in the EASI score relative to baseline, was achieved by all but one patient in the substudy treated with 300 mg of dupilumab versus none in the placebo group.42

Clinical improvement was associated with significant dose-dependent changes from baseline in the defined AD transcriptome (meant as the array of differentially expressed genes between lesional and non-lesional AD skin) detected in lesional skin by using microarrays in the dupilumab group compared with the placebo arm of the study.13 The altered expression detected in pretreatment lesional skin improved after dupilumab treatment, with 821 genes whose expression was modulated by 300 mg dupilumab versus 275 placebo-modulated probes.42 In particular, dupilumab downregulated a large set of genes codifying for inflammatory mediators and epidermal proliferation markers, while it upregulated genes involved in the structural, lipid metabolism, and barrier-related functions. Particularly, dupilumab was able to suppress key pathogenic circuits mediated by Th2-derived products, as demonstrated by the reduction in IL-4 and IL-13 levels at skin lesions observed in dupilumab-responder patients.42
not only to a Th2 and eosinophil response (e.g., CCL13 and CCL26) but also to the IL-17/IL-22 signaling and Th1 pathway. Overall, these mechanistic changes induced by dupilumab, including the suppression of immune cell activation (i.e., T cells, DCs, and eosinophils) and the amelioration of keratinocyte proliferation and differentiation, were correlated with clinical improvement of AD, and these effects were dose dependent in dupilumab-treated patients.

**Phase I and II studies**
The first controlled studies (Phase I and II) testing dupilumab for the treatment of AD were performed in 2014. In adults with moderate-to-severe AD, dupilumab, administered as 4- to 12-week monotherapy or in association with topical corticosteroids, achieved rapid and significant improvements.

Reduction in disease severity was observed, starting from the first week, obtaining 74% decrease in EASI after 12 weeks of treatment. Similarly, a significant reduction in pruritus levels (55.7% in the treatment group versus 15% in the placebo group) was noted, with positive repercussion on patients’ quality of life (Table 1). Clinical improvements were proportional to the drug dose. During the dupilumab treatment, early and sustained improvement of patient-reported outcomes (PROs) in sleep, mental health, and health-related quality of life were highlighted.

Safety data showed no evidence of drug-related serious adverse events or organ toxicity, with nasopharyngitis and headache among the most common side effects. The clinical improvement was correlated with Th2-related biomarker changes at serum and tissue levels and normalization of gene expression in lesional skin, appearing similar to the non-lesional gene expression profile. The latter data suggest that the epidermal abnormalities associated with AD might be somehow reduced with dupilumab treatment.

Overall, the vigorous effects of dupilumab in improving clinical and laboratory signs confirm the pivotal pathogenic role of IL-4 and IL-13 signaling in adulthood AD and further support the use of Th2 cytokine antagonists in the treatment of this disease.

**Phase III trials**
In 2016, two randomized, placebo-controlled, worldwide Phase III trials were conducted, enrolling 671 adult patients suffering from moderate-to-severe AD whose disease was inadequately controlled by topical treatment (patients suffering from AD variants were included, e.g., intrinsic, extrinsic, with early onset, or with late onset). In these studies, dupilumab significantly improved the signs and symptoms
<table>
<thead>
<tr>
<th>Phase III</th>
<th>16 weeks monotherapy (day 112) – SOLO1 study (receiving dupilumab every week or every other week)</th>
<th>4 weeks combination therapy (day 29)</th>
<th>EASI 50 in 100% dupilumab group versus 50% placebo</th>
<th>EASI 75 in 62% dupilumab group versus 40% placebo</th>
<th>Overall, improvement in EASI of 76% in the dupilumab group versus 53% placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EASI 75 in 52 weekly dupilumab group versus 15% placebo</td>
<td>EASI 50 in 100% dupilumab group versus 50% placebo</td>
<td>0 (clear) or 1 (almost clear) in 52% dupilumab group versus 30% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>≥4 points on numerical rating scale: in 40% of weekly dupilumab group versus 41% of every other week dupilumab group versus 12% placebo</td>
<td>≥4 points on numerical rating scale: in 39% of weekly dupilumab group versus 36% of every other week dupilumab group versus 8% placebo</td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 37% weekly dupilumab group versus 38% in every other week dupilumab group versus 15% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>EASI 75 in 48% weekly dupilumab group versus 12% placebo</td>
<td>EASI 75 in 62% dupilumab group versus 40% placebo</td>
<td>≥4 points on numerical rating scale: in 39% of weekly dupilumab group versus 36% of every other week dupilumab group versus 13% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 36% weekly dupilumab group versus 36% in every other week dupilumab group versus 13% placebo</td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 36% weekly dupilumab group versus 36% in every other week dupilumab group versus 13% placebo</td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 37% weekly dupilumab group versus 38% in every other week dupilumab group versus 15% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>≥4 points on numerical rating scale: in 40% of weekly dupilumab group versus 41% of every other week dupilumab group versus 12% placebo</td>
<td>≥4 points on numerical rating scale: in 39% of weekly dupilumab group versus 36% of every other week dupilumab group versus 8% placebo</td>
<td>≥4 points on numerical rating scale: in 40% of weekly dupilumab group versus 41% of every other week dupilumab group versus 25% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>EASI 75 in 52 weekly dupilumab group versus 15% placebo</td>
<td>EASI 75 in 62% dupilumab group versus 40% placebo</td>
<td>0 (clear) or 1 (almost clear) in 52% dupilumab group versus 30% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>≥4 points on numerical rating scale: in 40% of weekly dupilumab group versus 41% of every other week dupilumab group versus 12% placebo</td>
<td>≥4 points on numerical rating scale: in 39% of weekly dupilumab group versus 36% of every other week dupilumab group versus 8% placebo</td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 37% weekly dupilumab group versus 38% in every other week dupilumab group versus 15% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>EASI 75 in 48% weekly dupilumab group versus 12% placebo</td>
<td>EASI 75 in 62% dupilumab group versus 40% placebo</td>
<td>≥4 points on numerical rating scale: in 39% of weekly dupilumab group versus 36% of every other week dupilumab group versus 13% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 36% weekly dupilumab group versus 36% in every other week dupilumab group versus 13% placebo</td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 36% weekly dupilumab group versus 36% in every other week dupilumab group versus 13% placebo</td>
<td>0 or 1 (or reduction of ≥2 points from baseline) in 37% weekly dupilumab group versus 38% in every other week dupilumab group versus 15% placebo</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Abbreviations:** EASI, Eczema Area and Severity Index; VAS, visual analog scale; IGA, Investigator’s Global Assessment; BSA, body surface area; SCORAD, SCORing Atopic Dermatitis; GISS, Global Individual Sign Score; POEM, Patient-Oriented Eczema Measure; HADS, Hospital Anxiety and Depression Scale; DLQI, Dermatology Life Quality Index; N/A, not applicable.
of AD (improvement in EASI, SCORAD, body surface area [BSA], pruritus [visual analog scale {VAS}], Investigator’s Global Assessment [IGA], Global Individual Sign Score [GISS]) as well as scale value of anxiety, depression, and quality of life, as compared with placebo (Table 1).48

The data published are promising, and trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab.48

**New treatment era for AD**

The approval for the marketization of dupilumab is approaching, and it may offer a significant therapeutic advancement in AD treatment. Unlike the currently available systemic treatments, dupilumab is going to profoundly change the therapeutic paradigm and the long-term management of AD, inaugurating a novel efficacious targeted therapeutic approach for patients with moderate-to-severe AD. Similar to biologic agents approved for psoriasis, dupilumab seems to offer the opportunity of a long-term control of the disease, being effective and overall safe.33,36,37,40,43,48

Dupilumab recently received US Food and Drug Administration breakthrough therapy designation for AD, with ongoing trials in both adult and pediatric populations.33,40,43,48

Although the results of this study are thrilling, it is still not possible to translate the published results to the children, the most commonly affected population, since only patients aged >18 years were enrolled up to now.33,40,43,48 The future use of dupilumab in pediatric patients could potentially provide insights about its impact as early intervention in modifying the course of the disease.

Finally, pharmaco-economically, we do not know how much this medication will cost; compared to the other biologics used in dermatology, it would be thought that dupilumab will likely cost tens to thousands of euro per year, which is significantly higher than the currently available systemic medications.33 As a consequence, dupilumab will likely be reserved for cases of severe AD unresponsive to traditional modalities.33 Currently, there are no studies that compare dupilumab to other medications, and it is difficult to compare the results from Phase I, II, and III studies involving dupilumab to the results achieved with other drugs. The tolerability of dupilumab seems high, maybe higher than that of systemic medications available; even the long-term side effects are not known.

**Conclusion**

With no doubts, dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD and asthma.33,43,48 Interestingly, mepolizumab (anti-IL-5) and omalizumab (anti-IgE), which have been studied in asthma with the same success as that of dupilumab, did not achieve enough results in AD. This fact may underline a pivotal role of IL-4 and IL-13 among the Th-2 signal cytokines in AD.

Dupilumab initiates a decade that will be probably characterized by a great number of clinical trials in these areas, focusing not only on IL-4 and IL-13 but also on IL-31, IL-22, and TSLP, providing new hopes and insights for future therapeutic (and maybe prevention) approaches in AD.33,35,50

**Disclosure**

The authors declare no affiliation or significant financial involvement in any organizations or entity with a direct financial interest in the subject matter or materials discussed in the present manuscript. The authors report no conflicts of interest in this work.

**References**


27. Ring J, Alomar A, Bieber T, et al; European Dermatology Forum (EDF); European Academy of Dermatology and Venereology (EADV); European Federation of Allergy (EFA); European Task Force on Atopic Dermatitis (ETFA/EADV); European Society of Pediatric Dermatology (ESPD); Global Allergy and Asthma European Network (GAALEN). Guidelines for treatment of atopic eczema (atopic dermatitis) part I. *J Eur Acad Dermatol Venereol*. 2012;26(8):1045–1060.

